REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half-yearly Report

12 Dec 2008 07:00

To be released on 12 December 2008 Sterling Green Group Plc ("Sterling Green" or "the Group") Interim Results for the six month period ended 30 September 2008 Chairman's StatementIntroduction

I am pleased to present the Group's interim results for the six month period ended 30 September 2008.

Results and dividends

The Group generated an unaudited loss before and after taxation for the six month period of ‚£365,000 (six months to 30 September 2007 - ‚£756,000 loss) on revenues of ‚£931,000 (six months to 30 September 2007 - ‚£467,000).

In the first quarter of the new financial year it was evident that certain of the Group's operations required streamlining as a result of prevailing market conditions, in particular the well-publicised problems encountered in the mortgage industry. The ensuing cost-cutting process significantly improved the efficiency of the Group and, as a result, the loss generated in the second quarter of the current financial year was significantly less than that of the first quarter. Moreover, trading in the period since 30 September 2008 has, at an operating profit level, been broadly breakeven, although historically December and January have been the Group's weakest trading months, which is reflected in the Group's budget.

In September 2008 the Group replaced its bank overdraft facility with a ‚£ 250,000 loan facility with a third party at an interest rate of 18 per cent. per annum and as at 30 September 2008 the Group had drawn down ‚£200,000 of this loan. The balance of the loan was drawn down recently and the majority of these monies remain available for the Group's working capital requirements. The Directors still consider that this loan facility will be sufficient for the Group's short term working capital requirements, although given the high interest rate that has been applied to this loan the board are actively looking to refinance it in the short term. However, should the trading performance of the Group during the next six months be consistently lower than management's expectations, the Group is likely to require further funds.

The Directors do not recommend the payment of a dividend.

Outlook

The Directors have been actively looking to add to the Group's existing revenue streams. It is, however, too early in this process to be able to accurately assess the potential levels of income that could be generated from these sources and the possible impact on the Group's profitability.

The Group is currently constrained by its working capital position but is managing its available resources in order to take advantage of its reduced cost base and significant market opportunity.

The Directors consider that the downturn in economic activity is now adversely affecting the financial circumstances of an increasing number of members of the public and although this is bad news for the UK economy and the individuals and families concerned, it is a time when the service offered by our Group should be available to assist a growing number of additional clients in dealing with their financial problems.

Michael EdelsonChairman12 December 2008Enquiries:Sterling Green Group plc Tel: 0161 975 5757Michael Edelson John East & Partners Limited Tel: 020 7628 2200Simon Clements/David Worlidge

Consolidated Income Statement

For the six month period ended 30 September 2008

Six months e Six months 15 months nded 30 ended 30 ended 31 September September March 2008 2007 2008 (Unaudited) (Unaudited) (Audited) ‚£000 ‚£000 ‚£000 Revenue 931 467 1,309 Cost of sales (616) (502) (1,423) Gross profit/(loss) 315 (35) (114) Administrative expenses (667) (724) (1,538) Loss from operations (352) (759) (1,652) Finance income 4 11 24 Finance costs (17) (8) (20) Loss on ordinary activities before (365) (756) (1,648)taxation Income tax expense - - - Loss on ordinary activities after (365) (756) (1,648)taxation Loss per share - basic and diluted (0.13p) (0.31p) (0.70p)

STATEMENT OF CHANGES IN TOTAL EQUITY

FOR THE SIX MONTH PERIOD ENDED 30 SEPTEMBER 2008

Six months Six months 15 months ended 30 ended 30 ended 31 September September March 2008 2007 2008 (Unaudited) (Unaudited) (Audited) ‚£000 ‚£000 ‚£000 Total equity at the beginning of the 972 931 16period Loss for the period (365) (756) (1,648) Issue of share capital 200 1,013 2,763 Costs of share issue - (63) (159) Total equity at the end of the period 807 1,125 972CONSOLIDATED BALANCE SHEETAS AT 30 SEPTEMBER 2008 As at 30 As at As at September 2008 30 September 31 March (Unaudited) 2007 (Unaudited) 2008 (Audited) ‚£000 ‚£000 ‚£000 Non-current assets Goodwill 1,115 1,078 1,115 Property, plant and equipment 258 351 309 Total non-current assets 1,373 1,429 1,424 Current assets Trade and other receivables 89 199 141 Cash and cash equivalents 102 147 180 Total current assets 191 346 321 Current liabilities Trade and other payables (342) (350) (318) Current tax liabilities (18) (18) (18) Borrowings (86) (86) (284) Total current liabilities (446) (454) (620) Net current liabilities (255) (108) (299) Non-current liabilities Borrowings (311) (196) (153) Total non-current liabilities (311) (196) (153) Net assets 807 1,125 972 Equity Share capital 288 250 280 Share premium account 1,710 834 1,518 Capital reserve 6 6 6 Other reserves 891 891 891 Retained losses (2,088) (856) (1,723) Total equity 807 1,125 972

CONSOLIDATED CASH FLOW STATEMENT

FOR THE SIX MONTH PERIOD ENDED 30 SEPTEMBER 2008

Six months Six months 15 months ended 30 ended 30 ended 31 September September March 2008 2007 2008 (Unaudited) (Unaudited) (Audited) ‚£000 ‚£000 ‚£000 Cash flows from operating activities Loss before tax (365) (756) (1,648) Adjustments for: Depreciation of property, plant and 52 49 113equipment Decrease/(Increase) in trade and other 52 (39) (46)receivables Increase in trade and other payables 24 89 88 Finance income (4) (11) (24) Finance costs 17 8 20

Net cash used in operating activities (224) (660) (1,497)

Cash flow from investing activities Acquisition of subsidiary, net of cash - (29) (29)acquired Purchase of property, plant and (1) (59) (82)equipment Finance income 4 11 24 Net cash from/(used in) investing 3 (77) (87)activities Cash flow from financing activities Capital element of finance lease (42) (25) (68)payments Issue of ordinary share capital, net 200 (61) 1,593of costs Proceeds from new loans 200 - - Finance costs (17) (8) (20) Net cash from/(used in) financing 341 (94) 1,505activities Net increase/(decrease) in cash and 120 (831) (79)cash equivalents Cash and cash equivalents at beginning (18) 978 61of period Cash and cash equivalents at end of 102 147 (18)period

NOTES TO THE INTERIM REPORT

FOR THE SIX MONTH PERIOD ENDED 30 SEPTEMBER 2008

1. The interim financial statements have not been audited and they do not

constitute full financial statements within the meaning of s240 of the Companies Act 1985. The statutory accounts for the period ended 31 March 2008 have been delivered to the Registrar of Companies. The auditors' opinion on those accounts was unqualified and did not contain a statement under s237(2) or s237(3) of the Companies Act 1985.

2. The next accounting reference date will be 31 March 2009 and financial

statements for this period will be prepared in accordance with International Financial Reporting Standards (IFRS) as required by European Law. The interim financial statements have been prepared in accordance with accounting policies that are expected to apply to the financial statements for the year ending 31 March 2009.

3. Basic loss per share has been calculated using a loss for the period of ‚£

365,000 (‚£756,000 loss for the six month period ended 30 September 2007 and ‚£ 1,648,000 loss for the 15 month period ended 31 March 2008) and a weighted average number of ordinary shares in issue during the six month period ended 30 September 2008 of 287,844,242 (240,486,537 for the six month period ended 30 September 2007 and 235,986,036 for the 15 month period ended 31 March 2008). Diluted loss per share is calculated by adjusting the weighted average number of ordinary shares in issue assuming conversion of all dilutive potential ordinary shares. The Company's potential ordinary shares consist of share options and deferred consideration shares. Due to the loss in the current and comparative periods there are no dilutive ordinary shares.

5. Copies of the Interim Report can be obtained by writing to The Company

Secretary, Sterling Green Group plc, Number 14, The Embankment, Vale Road,

Heaton Mersey, Stockport, Cheshire SK4 3GN. Alternatively, copies can also be

downloaded from the Company's website which is www.sterlinggreen.co.uk.

vendor
Date   Source Headline
6th Jan 20225:30 pmRNSAmryt Pharma
6th Jan 20227:00 amGNWKey Dates for AIM Delisting
4th Jan 202212:00 pmGNWThe Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
4th Jan 20227:00 amGNWTotal Voting Rights
1st Dec 20217:00 amGNWTotal Voting Rights
30th Nov 20217:00 amGNWDirector/PDMR Shareholding
23rd Nov 202112:00 pmGNWAmryt Provides Update on Regulatory Review Process for Oleogel-S10
22nd Nov 20217:00 amGNWAmryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM
3rd Nov 202111:00 amGNWAmryt Reports Strong Q3 2021 Results
1st Nov 20211:00 pmGNWTotal Voting Rights
1st Nov 20217:00 amRNSAmryt Supports Acromegaly Awareness Day
22nd Oct 20217:00 amRNSAmryt Supports Global EB Awareness Week 2021
20th Oct 202112:00 pmGNWAmryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3
19th Oct 202112:00 pmGNWAmryt Announces New Patents for Oleogel-S10 and Mycapssa®
23rd Sep 202112:00 pmRNSAmryt Supports Global FH Awareness Day
13th Sep 202112:00 pmGNWAmryt Raises Full Year 2021 Revenue Guidance to $220M - $225M
1st Sep 20217:00 amGNWTotal Voting Rights
19th Aug 20217:00 amGNWAmryt Issues Ordinary Shares and Total Voting Rights
13th Aug 20211:23 pmRNSHolding(s) in Company - Replacement
11th Aug 202111:30 amRNSHoldings in Company
11th Aug 202110:36 amRNSHolding(s) in Company
10th Aug 20212:20 pmGNWDirector/PDMR Shareholding
10th Aug 20219:53 amRNSHolding(s) in Company
9th Aug 202112:00 pmGNWAmryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT
6th Aug 202112:00 pmGNWAmryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance
5th Aug 20213:50 pmGNWAmryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights
28th Jul 20213:00 pmGNWResult of General Meetings
12th Jul 202112:00 pmGNWAmryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6
28th Jun 202112:00 pmGNWPublication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
15th Jun 202111:45 amGNWAmryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
7th Jun 202112:00 pmGNWFDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting
3rd Jun 20217:00 amGNWFDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
2nd Jun 20211:30 pmGNWAmryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
5th May 20214:41 pmRNSSecond Price Monitoring Extn
5th May 20214:35 pmRNSPrice Monitoring Extension
5th May 202112:05 pmGNWAmryt Reports Record Q1 2021 Financial and Operating Results
5th May 202112:00 pmGNWAmryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases
15th Apr 202112:00 pmGNWAmryt to Report Q1 2021 Results and Host Conference Call & Webcast on May 5
6th Apr 20217:00 amGNWAmryt Announces the Appointment of Sheila Frame as President Americas
31st Mar 202111:00 amRNSAmryt Supports World Lipodystrophy Day
31st Mar 20217:00 amGNWAmryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®)
30th Mar 20217:00 amGNWAmryt Announces Results from an Investigator Sponsored Study of Lomitapide in FCS
29th Mar 20217:00 amGNWAmryt Announces Validation of its MAA by the EMA for Oleogel-S10* (Filsuvez®)
23rd Mar 20217:00 amGNWAmryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy
22nd Mar 20217:00 amGNWAmryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin)
15th Mar 202110:00 amGNWDirector/PDMR Shareholding
12th Mar 20217:00 amGNWExercise of Options and Total Voting Rights
11th Mar 202111:30 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
8th Mar 20216:00 pmGNWDirector/PDMR Shareholding
8th Mar 20217:00 amGNWAmryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.